Ecallantide

Nature Reviews Drug Discovery

Volumn 9, Issue 3, 2010, Pages 189-190

  Zuraw, Bruce ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECALLANTIDE; KALLIKREIN;

ANGIONEUROTIC EDEMA; DRUG APPROVAL; DRUG INDICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT SURVEY;

ANGIOEDEMAS, HEREDITARY; HUMANS; MODELS, BIOLOGICAL; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, BRADYKININ B2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77649211092     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3125     Document Type: Short Survey

References (10)

1. Davis, A. E. 3rd. New treatments addressing the pathophysiology of hereditary angioedema. Clin. Mol. Allergy 6, 2 (2008).
2. Schneider, L. et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120, 416-422 (2007).
3. Bork, K., Yasothan, U & Kirkpatrick, P. Icatibant. Nature Rev. Drug Discov. 7, 801-802 (2008).
4. Nussberger, J. et al. Plasma bradykinin in angiooedema. Lancet 351, 1693-1697 (1998).
5. US Food and Drug Administration. FDA labelling information - Kalbitor (ecallantide). FDA website [online], http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/125277lbl.pdf (2009).
6. Ley, A. C. et al. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein. Mol. Divers. 2, 119-124 (1996).
7. Markland W. et al. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 35, 8058-8067 (1996).
8. IMS MIDAS (IMS Health, 2009).
9. Nadeau, P. et al. SG Cowen Biotechnology Report (6 Jan 2010).
10. Monane, M. et al. Needham Investment Analysis (2 Dec 2009).